We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Prospective Epidemiological Study Of The Prevalence Of HLA-B*5701

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00453440
First Posted: March 29, 2007
Last Update Posted: September 12, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
GlaxoSmithKline
Information provided by (Responsible Party):
ViiV Healthcare
March 28, 2007
March 29, 2007
September 12, 2017
March 20, 2007
August 10, 2007   (Final data collection date for primary outcome measure)
Prevalence of HLA-B*5701 in the UK population via central labs [ Time Frame: 2 Hours ]
The widespread of HLA-B*5701 applied in the selected area in each participant of the UK population was tested via central labs. The result is summarized here.
Prevalence of HLA-B*5701 in the UK population via central labs
Complete list of historical versions of study NCT00453440 on ClinicalTrials.gov Archive Site
  • Prevalence of HLA-B*5701 in major UK ethnotypes in the study population. [ Time Frame: 2 Hours ]
  • Description of HLA-B*5701 in the UK population via local labs. [ Time Frame: 2 Hours ]
  • Prevalence of HLA-B*5701 in major UK ethnotypes in the study population.
  • Description of HLA-B*5701 in the UK population via local labs.
Not Provided
Not Provided
 
Prospective Epidemiological Study Of The Prevalence Of HLA-B*5701
Prospective Epidemiological Study of the Prevalence of HLA-B*5701 in HIV-1 Infected UK Patients

This is a study to determine the prevalence of a genetic marker, HLA-B5701, in the UK population. HLA-B*5701 has been strongly associated with the risk of an allergic reaction to a HIV medicine, Abacavir. The allergic reaction is known as a hypersensitivity reaction.

The study is a prospective study inviting HIV-1 positive patients over the age of 18 years to participate. Each participant will complete one study visit. They will be asked for details of their background including their age, sex, ethnicity, country of origin and parental country of origin.

They will be asked to give two samples to test for the presence of the genetic marker HLA-B*5701. The two samples are:

  • A cheek swab
  • A blood sample

In selected centres patients may be asked to provide up to two additional blood samples. These samples will be used to help develop and validate new methods of determining HLA-B*5701 testing.

Not Provided
Observational
Not Provided
Not Provided
Not Provided
Not Provided
Not Provided
Infection, Human Immunodeficiency Virus
Procedure: Cheek swab & blood test
Cheek swab & blood test
Not Provided
Orkin C, Sadiq ST, Rice L, Jackson F; UK EPI team. Prospective epidemiological study of the prevalence of human leukocyte antigen (HLA)-B*5701 in HIV-1-infected UK subjects. HIV Med. 2010 Mar;11(3):187-92. doi: 10.1111/j.1468-1293.2009.00762.x. Epub 2009 Sep 24.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
1502
August 10, 2007
August 10, 2007   (Final data collection date for primary outcome measure)

Inclusion criteria:

  • HIV-1 infected patients over 18 years of age
  • Patient willing & able to understand and provide written informed consent

Exclusion criteria:

Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United Kingdom
 
 
NCT00453440
CNA109479
No
Not Provided
Not Provided
ViiV Healthcare
ViiV Healthcare
GlaxoSmithKline
Study Director: GSK Clinical Trials ViiV Healthcare
ViiV Healthcare
September 2017